J&J Levaquin tenth indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson's antibiotic Levaquin is approved May 23 for treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis or Staphylococcus epidermidis, making the tenth indication for the product. Levofloxacin is the first once-daily fluoroquinolone to receive the indication, the company says. J&J estimates that 35% of men aged 50 and older may have chronic prostatitis...